<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01398046</url>
  </required_header>
  <id_info>
    <org_study_id>Dasatinib-63-03</org_study_id>
    <nct_id>NCT01398046</nct_id>
  </id_info>
  <brief_title>Effects of Gastric pH on the Pharmacokinetics of Dasatinib</brief_title>
  <official_title>Effects of Gastric pH on the Pharmacokinetics of Dasatinib in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to evaluate the ability of a natural supplement (betaine&#xD;
      hydrochloride) to affect the absorption of dasatinib in healthy volunteers. The investigators&#xD;
      predict that betaine hydrochloride will increase the absorption of dasatinib, in volunteers&#xD;
      pre-treated with proton-pump inhibitors (PPIs).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area-Under-the Concentration Curve from zero-to-twenty two hours (AUC,0-22) of Dasatinib</measure>
    <time_frame>Day 4</time_frame>
    <description>The primary outcome measure will be dasatinib area-under-the-concentration curve (AUC) values from zero-to-twenty two (0-22) hours. Values from Experiemntal Arms of the study (Dasatinib plus Rabeprazole; Dasatinib plus Rabeprazole AND Betaine Hydrochloride) will be compared against the active comparator (dasatinib alone) and tested for statistical significance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area-Under-the Concentration Curve from zero-to-infinity (AUC,0-inf) of Dasatinib</measure>
    <time_frame>Day 4</time_frame>
    <description>The primary outcome measure will be dasatinib area-under-the-concentration curve (AUC) values from zero-to-infinite time (0-inf). Values from Experiemntal Arms of the study (Dasatinib plus Rabeprazole; Dasatinib plus Rabeprazole AND Betaine Hydrochloride) will be compared against the active comparator (dasatinib alone) and tested for statistical significance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration of Dasatinib</measure>
    <time_frame>Day 4</time_frame>
    <description>The maximum plasma concentration (Cmax) will also be measured. Values from Experiemntal Arms of the study (Dasatinib plus Rabeprazole; Dasatinib plus Rabeprazole AND Betaine Hydrochloride) will be compared against the active comparator (Dasatinib alone) and tested for statistical significance.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dasatinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dasatinib plus Rabeprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dasatinib plus Rabeprazole AND Betaine Hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>dasatinib (100mg) PO x1</description>
    <arm_group_label>Dasatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib plus Rabeprazole</intervention_name>
    <description>Rabeprazole (20mg) PO twice daily (Days 1-3); Dasatinib (100mg) PO x1 (Day 4)</description>
    <arm_group_label>Dasatinib plus Rabeprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib plus Rabeprazole AND Betaine Hydrochloride</intervention_name>
    <description>Rabeprazole (20mg) PO twice daily (Days 1-3); Betaine Hydrochloride (1500mg) PO x1 AND Dasatinib (100mg) PO x1 on Day 4</description>
    <arm_group_label>Dasatinib plus Rabeprazole AND Betaine Hydrochloride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female 18-59 years of age&#xD;
&#xD;
          -  Healthy adult with no active medical problems or significant chronic diseases as&#xD;
             determined by the study doctor based on history, physical exam and laboratory&#xD;
             evaluations&#xD;
&#xD;
          -  BMI between 18.5-30 kg/m2&#xD;
&#xD;
          -  Taking no medications 2 weeks before and during the study enrollment, including drugs&#xD;
             of abuse, prescription or over-the-counter (OTC) medications (except acetaminophen)&#xD;
&#xD;
          -  Subjects able to maintain adequate birth control during the study independent of&#xD;
             hormonal contraceptive use&#xD;
&#xD;
          -  Be able to provide written informed consent and comply with requirements of the study&#xD;
&#xD;
          -  Avoid eating grapefruit and drinking grapefruit juice from 7 days before the first&#xD;
             study day until the completion of the entire study&#xD;
&#xD;
          -  Abstinence from alcoholic beverages, caffeinated beverages and orange juice from 3pm&#xD;
             the night before a study day until completion of that study day&#xD;
&#xD;
          -  Fast from food and beverages at least 8 hours prior to medication dosing&#xD;
&#xD;
          -  Be able to read, speak, and understand English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with a history of gastrointestinal disease including gastroesophageal reflux&#xD;
             disease, gastritis, peptic ulcer disease, or dyspepsia&#xD;
&#xD;
          -  Subjects with a fasting gastric pH of &gt; 4 (i.e. hypochlorhydria)&#xD;
&#xD;
          -  Subjects with a history of dysphagia, achalasia, or difficulty swallowing capsules,&#xD;
             tablets, or pills&#xD;
&#xD;
          -  Subjects on prescription or chronic over-the-counter (OTC) medications (including&#xD;
             hormonal contraceptives)&#xD;
&#xD;
          -  Subjects with known allergies to rabeprazole or any other proton pump inhibitors&#xD;
             (PPI's) or betaine hydrochloride&#xD;
&#xD;
          -  Subjects who smoke tobacco&#xD;
&#xD;
          -  Subjects with ongoing alcohol or illegal drug use&#xD;
&#xD;
          -  Subjects who are pregnant, lactating, or attempting to conceive&#xD;
&#xD;
          -  Subjects unable to maintain adequate birth control during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leslie Z Benet, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lynda Frassetto, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Center, UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>July 5, 2011</study_first_submitted>
  <study_first_submitted_qc>July 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2011</study_first_posted>
  <last_update_submitted>April 24, 2015</last_update_submitted>
  <last_update_submitted_qc>April 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dasatinib</keyword>
  <keyword>betaine</keyword>
  <keyword>betaine hydrochloride</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>healthy volunteer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
    <mesh_term>Rabeprazole</mesh_term>
    <mesh_term>Betaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

